From: Pamela D Berens <<a href="/SCRIPTS/WA-LSOFTDONATIONS.EXE?LOGON=A3%3D0012D%26L%3DLACTNET%26E%3D7bit%26P%3D21680%26B%3D----40b47aaf28cf37e3%26T%3Dtext%2Fplain%3B%2520charset%3D%26pending%3D" target="_parent" >[log in to unmask]</a>>
To: <a href="/SCRIPTS/WA-LSOFTDONATIONS.EXE?LOGON=A3%3D0012D%26L%3DLACTNET%26E%3D7bit%26P%3D21680%26B%3D----40b47aaf28cf37e3%26T%3Dtext%2Fplain%3B%2520charset%3D%26pending%3D" target="_parent" >[log in to unmask]</a>
Message-ID: <<a href="/SCRIPTS/WA-LSOFTDONATIONS.EXE?LOGON=A3%3D0012D%26L%3DLACTNET%26E%3D7bit%26P%3D21680%26B%3D----40b47aaf28cf37e3%26T%3Dtext%2Fplain%3B%2520charset%3D%26pending%3D" target="_parent" >[log in to unmask]</a>>
Date: Fri, 22 Dec 2000 22:43:32 -0600
X-Mailer: Netscape Webmail
MIME-Version: 1.0
Content-Language: en
Subject: budesonide
X-Accept-Language: en
Content-Type: text/plain; charset=us-ascii
Content-Disposition: inline
Content-Transfer-Encoding: 7bit

The following information is taken from Dr. Hale's 2000 text.  It lists
budesonide (brand name Rhinocort or Pulmicort) as category L3 or
"moderately safe" for use in breastfeeding mothers.  When used
intranasally - less than 20% of the dose reaches systemic absorption.
Using commonly prescribed doses of this medication in intranasal form
would be unlikely to result in a dose that would be clinically
significant to the breastfed infant.  No adverse pediatric events have
been reported from use in breastfeeding mothers and this drug is used
in pediatrics down to age 6.  It is not well absorbed orally (about 10%
of dose).  Unfortunately, I have deleted the original post - was this
mother using this drug intranasally? Hope this information is helpful.
Pamela Berens  M.D. (OB/GYN)